Providing infrastructure and expertise through a unique collaborative model, enabling companies to develop their own manufacturing capabilities and systems for large-scale, clinical and commercial cell and gene therapy supply.

Contributing to national COVID-19 vaccine response and driving innovation into large scale cell and gene therapy manufacturing and technology transfer.